F93. CYP2D6 Revisited in GENDEP, a Multicenter Clinical Trial of Nortriptyline and Escitalopram

The polymorphic CYP2D6 enzyme is estimated to be responsible for the oxidation of 20-25% of all drugs in clinical use. However, genotyping for its variants is not routinely clinically available. The gene is particularly complex, with different platforms analysing different subsets of variants. GENDEP (Genome-based therapeutic drugs for depression) is a multicentre clinical trial which found an association between CYP2D6 genotype and nortriptyline concentration, but no association between CYP2D6 or CYP2C19 and response to nortriptyline.

Source: Biological Psychiatry - May 13, 2019 Category: Psychiatry Authors: Katherine Aitchison, Rohit J. Lodhi, Yabing Wang, Beatriz Carvalho Henriques, Xiuying Hu, Dawon Lee, Diego Lomnitzer Lapetina, Joanna Hauser, Wolfgang Maier, Mojca Z. Dernovsek, Neven Henigsberg, Daniel Souery, Annamaria Cattaneo, Ole Mors, Marcella Riets Source Type: research